Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Mednax

Share:
Related MD
US Stock Futures Edge Lower Ahead Of ADP Report
MEDNAX Announces Acquisition of Pediatric Ear, Nose and Throat Practice in Houston
MEDNAX's (MD) CEO Roger Medel Discusses Q2 2015 Results - Earnings Call Transcript (Seeking Alpha)

In a report published Friday, Bank of America Merrill Lynch reiterated its Buy rating on Mednax (NYSE: MD), and raised its price target from $89.00 to $95.00.

BofA Merrill Lynch noted, “MD announced it acquired South Oakland Anesthesia Associates in Michigan with 73 anesthesiologists. This is the 7th anesthesia practice acquisition in 2012, bringing the company to its goal of spending $200m on anesthesia deals this year. MD paid cash and expects the deal to be immediately accretive to earnings. We estimate the deal could add $0.15 to EPS over time, one of the more sizable transactions for the company (Anesthesia Medical Alliance of East Tennessee closed on 7/30 was slightly bigger). Since our model does not include anesthesia deals (includes pediatric deals) we are raising our 2013/14 EPS estimates to $5.80/$6.44 from $5.68/$6.29 to reflect today's announcement, and raising our PO to $95 from $89 to reflect the higher numbers and better visibility into the anesthesia deal pipeline. We continue to like MD given the potential upside from deals while we wait for payer mix to stabilize.”

Mednax closed on Thursday at $81.35.

Latest Ratings for MD

DateFirmActionFromTo
May 2015Raymond JamesMaintainsOutperform
Feb 2015Stifel NicolausUpgradesHoldBuy
Jan 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Related Articles (MD)

Get Benzinga's Newsletters